SCYNEXIS, Inc. (SCYX): Price and Financial Metrics


SCYNEXIS, Inc. (SCYX): $2.45

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SCYX POWR Grades

  • Growth is the dimension where SCYX ranks best; there it ranks ahead of 88.33% of US stocks.
  • The strongest trend for SCYX is in Quality, which has been heading down over the past 178 days.
  • SCYX's current lowest rank is in the Quality metric (where it is better than 1.57% of US stocks).

SCYX Stock Summary

  • SCYX's price/sales ratio is 19.21; that's higher than the P/S ratio of 93.97% of US stocks.
  • Revenue growth over the past 12 months for SCYNEXIS INC comes in at -66.86%, a number that bests only 2.75% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SCYX comes in at -103.45% -- higher than that of only 5.71% of stocks in our set.
  • Stocks that are quantitatively similar to SCYX, based on their financial statements, market capitalization, and price volatility, are HTGM, WPRT, IRBT, SOFO, and BKYI.
  • SCYX's SEC filings can be seen here. And to visit SCYNEXIS INC's official web site, go to www.scynexis.com.

SCYX Valuation Summary

  • SCYX's price/sales ratio is 19.2; this is 860% higher than that of the median Healthcare stock.
  • Over the past 104 months, SCYX's price/sales ratio has gone up 14.7.

Below are key valuation metrics over time for SCYX.

Stock Date P/S P/B P/E EV/EBIT
SCYX 2022-11-25 19.2 4.6 -1.0 -0.8
SCYX 2022-11-23 19.2 4.6 -1.0 -0.8
SCYX 2022-11-22 19.3 4.7 -1.0 -0.8
SCYX 2022-11-21 19.5 4.7 -1.0 -0.8
SCYX 2022-11-18 17.8 4.3 -1.0 -0.7
SCYX 2022-11-17 16.2 3.9 -0.9 -0.6

SCYX Growth Metrics

    The year over year net income to common stockholders growth rate now stands at 36.36%.
  • The 5 year price growth rate now stands at -72.25%.
  • The 4 year price growth rate now stands at -72.25%.
SCYX's revenue has moved up $3,908,000 over the prior 52 months.

The table below shows SCYX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 4.164 -82.597 -77.623
2022-06-30 3.123 -76.675 -48.644
2022-03-31 1.8 -69.789 -33.641
2021-12-31 13.163 -54.56 -32.866
2021-09-30 12.566 -45.612 -46.334
2021-06-30 12.05 -38.895 -44.82

SCYX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SCYX has a Quality Grade of C, ranking ahead of 29.3% of graded US stocks.
  • SCYX's asset turnover comes in at 0.134 -- ranking 232nd of 682 Pharmaceutical Products stocks.
  • ACER, QURE, and MNOV are the stocks whose asset turnover ratios are most correlated with SCYX.

The table below shows SCYX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.134 1 -3.908
2021-03-31 0.169 1 -5.208
2020-12-31 0.000 NA -3.192
2020-09-30 0.000 NA -1.322
2020-06-30 0.000 NA -1.486
2020-03-31 0.001 1 -1.353

SCYX Price Target

For more insight on analysts targets of SCYX, see our SCYX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.36 Average Broker Recommendation 1.36 (Strong Buy)

SCYX Stock Price Chart Interactive Chart >

Price chart for SCYX

SCYX Price/Volume Stats

Current price $2.45 52-week high $7.87
Prev. close $2.45 52-week low $1.70
Day low $2.42 Volume 124,400
Day high $2.50 Avg. volume 189,444
50-day MA $2.40 Dividend yield N/A
200-day MA $2.74 Market Cap 80.01M

SCYNEXIS, Inc. (SCYX) Company Bio


SCYNEXIS, Inc., a pharmaceutical company, develops and commercializes novel anti-infectives to address unmet therapeutic needs. Its lead product candidate includes SCY-078, which is in Phase I clinical trials of the intravenous formulation; Phase II clinical trials for the treatment of invasive candida infections; and Phase II clinical trials for unmet medical needs, such as vulvovaginal candidiasis. The company was founded in 1999 and is based in Jersey City, New Jersey.


SCYX Latest News Stream


Event/Time News Detail
Loading, please wait...

SCYX Latest Social Stream


Loading social stream, please wait...

View Full SCYX Social Stream

Latest SCYX News From Around the Web

Below are the latest news stories about SCYNEXIS INC that investors may wish to consider to help them evaluate SCYX as an investment opportunity.

SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats

BARDA is seeking to support the development of broad-spectrum, oral/IV antifungal drug candidates with novel mechanisms of action that target Candida species, including Candida auris, and Aspergillus species.Ibrexafungerp, a first-in-class, broad-spectrum oral/IV antifungal meets all the priorities outlined by BARDA in its new Broad Agency Announcement (BAA) released this week, and has shown activity against multiple drug-resistant pathogens, including C. auris, C. albicans, C. glabrata, C. para

Yahoo | November 17, 2022

SCYNEXIS Third Quarter 2022 Earnings: Misses Expectations

SCYNEXIS ( NASDAQ:SCYX ) Third Quarter 2022 Results Key Financial Results Net loss: US$29.6m (loss widened by US$29.0m...

Yahoo | November 11, 2022

Ladenburg Thalmann & Co. Reaffirms Their Buy Rating on SCYNEXIS (SCYX)

E ratio of -1.13.

Christine Brown on TipRanks | November 10, 2022

Analysts’ Top Healthcare Picks: Larimar Therapeutics (LRMR), SCYNEXIS (SCYX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Larimar Therapeutics (LRMR – Research Report) and SCYNEXIS (SCYX – Research Report) with bullish sentiments. Larimar Therapeutics (LRMR) JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Larimar Therapeutics today and set a price target of $16.00. The company's shares closed last Thursday at $3.07, close to its 52-week low of $1.53. According to TipRanks.com, Wolleben is ranked 0 out of 5 stars with an average return of -38.9% and a 14.0% success rate.

Christine Brown on TipRanks | November 10, 2022

Scynexis (SCYX) Reports Q3 Loss, Misses Revenue Estimates

Scynexis (SCYX) delivered earnings and revenue surprises of -21.57% and 17.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 9, 2022

Read More 'SCYX' Stories Here

SCYX Price Returns

1-mo 1.24%
3-mo -3.16%
6-mo 15.02%
1-year -66.89%
3-year -77.31%
5-year -87.69%
YTD -59.84%
2021 -20.26%
2020 -15.93%
2019 89.58%
2018 -79.31%
2017 -27.27%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7468 seconds.